Carolyn Logan, President and Chief Executive Officer, stated, “Salix is committed to aggressively protecting its COLAZAL business and growing market share ...
Generic drug developer Mylan Inc. said Monday the Food and Drug Administration approved its version of Salix Pharmaceuticals Ltd.'s key drug Colazal. ...
Carolyn Logan, President and Chief Executive Officer, stated, “Salix is committed to aggressively protecting its COLAZAL business and growing market share ...
Salix Pharmaceuticals, Ltd. (SLXP) announced that Watson Pharma, Inc. will market and sell an authorized generic of COLAZAL(R) (balsalazide disodium) ...
... market and sell an authorized generic of Colazal, Salix's anti-inflammatory drug for the treatment of mildly to moderately active ulcerative colitis. ...
... near Pittsburgh in Cecil Township, said the 75-milligram balsalazide capsules are the generic version of Salix Pharmaceuticals Ltd.'s Colazal capsules. ...
Balsalazide disodium capsules are the generic version of Salix Pharmaceuticals' (NASDAQ: SLXP | charts | news | PowerRating) Colazal Capsules, which had US ...
Mylan (NYSE: MYL), Apotex, and Roxane have received FDA clearance to market their own generic versions of SLXP's Colazal. SLXP is recently down $1.01 to ...
O: Quote, Profile, Research) Colazal capsules received final regulatory approval. Mylan said Colazal capsules, which treats mild to moderate ulcerative ...
Colazal sales climbed to US$31.1 million during the third quarter and accounted for nearly half of Salix's revenue. Mylan's generic Colazal will enter the ...